Asset Details
Do you wish to reserve the book?
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Do you wish to request the book?
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
2019
Overview
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 10
9
/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim
vs
. eltrombopag (
P
= 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50%
vs
. 2.2%,
P
< 0.001), and to previous splenectomy in younger patients (100%
vs
. 33%,
P
= 0.001). Receiving romiplostim as first TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help clinicians make appropriate treatment decisions in the management of adult ITP patients with TPO-RA.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Agonists
/ Drugs
/ Female
/ Humanities and Social Sciences
/ Humans
/ Hydrazines - therapeutic use
/ Idiopathic thrombocytopenic purpura
/ Male
/ Patients
/ Purpura, Thrombocytopenic, Idiopathic - blood
/ Purpura, Thrombocytopenic, Idiopathic - drug therapy
/ Purpura, Thrombocytopenic, Idiopathic - pathology
/ Receptors, Fc - therapeutic use
/ Receptors, Thrombopoietin - agonists
/ Recombinant Fusion Proteins - therapeutic use
/ Science
